Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

430
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
430
Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Cancer Vaccines01:30

Cancer Vaccines

363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

The Journal of experimental medicine·2026
Same author

[Cardiac sarcoidosis in 2026 : current perspectives].

Revue medicale suisse·2026
Same author

Targeting PD-1<sup>+</sup> T cells with chimeric antigen receptors to reduce the HIV reservoir.

Science advances·2026
Same author

Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder.

Frontiers in immunology·2026
Same author

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Soluble CD14 and Lipopolysaccharide-Binding Protein Are Not Superior to Soluble CD25 as Biomarkers for Sarcoidosis.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

[CAR-T therapy for autoimmune diseases].

Ana Alcaraz-Serna1, Raphael Porret1, Lionel Trueb2

  • 1Service d'immunologie et allergie, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.

Revue Medicale Suisse
|April 3, 2024
PubMed
Summary

Chimeric Antigen Receptor (CAR)-T therapy, successful in blood cancers, shows promise for autoimmune diseases like lupus. Early trials indicate long-lasting remissions, driving further clinical research into this innovative treatment.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504

Related Experiment Videos

Last Updated: Jun 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Chimeric Antigen Receptor (CAR)-T cell therapy has transformed hematologic malignancy treatment.
  • Its success prompts investigation into severe autoimmune diseases resistant to standard therapies.
  • Systemic lupus erythematosus (SLE) is a key focus, with promising initial remission data.

Approach:

  • This review examines the scientific rationale for applying CAR-T cell therapy to autoimmune conditions.
  • It details the specific autoimmune diseases being targeted.
  • The review also addresses the potential risks associated with these advanced therapies.

Key Points:

  • CAR-T therapy involves genetically modifying T lymphocytes to target specific antigens.
  • Initial studies in systemic lupus erythematosus (SLE) demonstrate significant and potentially durable remissions.
  • The expansion of clinical trials highlights the growing interest and potential of CAR-T in autoimmune disease treatment.

Conclusions:

  • CAR-T cell therapy offers a novel and potentially curative approach for refractory autoimmune diseases.
  • Further research and clinical trials are essential to fully understand its efficacy and safety profile.
  • This therapeutic strategy represents a paradigm shift in managing complex autoimmune conditions.